LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced five presentations featuring botensilimab (BOT, an Fc-enhanced anti-CTLA-4 antibody) plus ...
Results from two independent neoadjuvant studies in the U.S. and Europe, enrolling more than 80 patients, underscore BOT/BAL’s potential to enable chemo-free and non-operative approaches in colorectal ...
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its End-of-Year 2025 Stakeholder Webcast on Wednesday, December 3, 2025 at 4:00 p.m. ET. The session ...
Presentations will showcase new data reinforcing BOT/BAL’s potential across different lines of treatment in colorectal cancer, including the neoadjuvant setting LEXINGTON, Mass., December 18, ...
LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today shared new data on botensilimab (BOT) and balstilimab (BAL) at the American Society of Clinical ...
Presentations will showcase new data reinforcing BOT/BAL’s potential across different lines of treatment in colorectal cancer, including the neoadjuvant setting Agenus Inc. (Nasdaq: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback